Pre-made Plonmarlimab benchmark antibody ( Whole mAb, anti-CSF2 therapeutic antibody, Anti-CSF/GMCSF Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-453

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-453 Category Tag

Product Details

Pre-Made Plonmarlimab biosimilar, Whole mAb, Anti-CSF2 Antibody: Anti-CSF/GMCSF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Plonmarlimab [previously TJM 2 (TJ 003234)] is a first-in-class, humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting neutralise.

Products Name (INN Index)

Pre-Made Plonmarlimab biosimilar, Whole mAb, Anti-CSF2 Antibody: Anti-CSF/GMCSF therapeutic antibody

INN Name

Plonmarlimab

Target

CSF2

Format

Whole mAb

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II/III

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2020

Companies

I-Mab Biopharma

Conditions Approved

NA

Conditions Active

Rheumatoid arthritis,COVID-19,Osteoarthritis

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

CSF2

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide